New England Drug Discovery Partners — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

New England Drug Discovery Partners (NEDP) is a Boston-based, privately-held Contract Research Organization (CRO) founded in 2016 (with conflicting data suggesting 2012). The company leverages a team of experienced pharmaceutical chemists to offer discovery-stage chemistry services, including lead optimization, custom synthesis, and process development. Its business model is purely service-based, generating revenue by partnering with external clients rather than developing its own therapeutic assets. NEDP positions itself as a high-value, relationship-driven partner for solving complex chemical problems in drug development.

Drug DeliverySmall Molecules

Technology Platform

Knowledge-based platform of synthetic organic and medicinal chemistry expertise, offering services in discovery chemistry, process chemistry, and custom synthesis.

Opportunities

The growing trend of pharmaceutical and biotech outsourcing creates sustained demand for high-end chemistry services.

Integration within the Genesis Global Group offers potential to provide clients with a more seamless path from discovery chemistry to clinical development services.

Risk Factors

Revenue is vulnerable to client concentration and fluctuations in overall biopharma R&D spending.

The company operates in a highly competitive CRO market and is dependent on recruiting and retaining specialized scientific talent.

Competitive Landscape

NEDP competes in the crowded drug discovery CRO space, facing competition from large, full-service global CROs (e.g., Charles River, Labcorp) and numerous niche chemistry-focused service providers. Its differentiation is based on deep scientific expertise, a relationship-driven model, and a track record of solving complex chemical problems.

More companies in United States →